AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04066725
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given ASA 81 mg orally once daily for a total of 60 days
Trial: NCT04066725
Drug: Aspirin 325mg
RxNorm normalized name: ASPIRIN 325MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given ASA 325 mg orally once daily for a total of 60 days
Trial: NCT03020979
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 500mg apatinib daily orally.
Trial: NCT02106182
Drug: Silodosin
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03795194
Drug: ampicillin/clavulanate
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA-approved antibiotic
Trial: NCT00681213
Drug: Tacrolimus/MMF
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00681213
Drug: Neoral/Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00894543
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
Trial: NCT01643616
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
Trial: NCT01643616
Drug: Prilocaine 1%
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
Trial: NCT01643616
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
Trial: NCT01643616
Drug: Prilocaine 1%
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10ml Prilocaine 1% for saphenous nerve block
Trial: NCT04249076
Drug: Clobetasol Propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
Trial: NCT01381731
Drug: diquafosol tetrasodium ophthalmic solution 2%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: opthalmic solution 2 drops in each eye QID
Trial: NCT00010036
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00010036
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04563624
Drug: composite blocks
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cad cam composite blocks
Trial: NCT04563624
Drug: ceramic cad cam blocks
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ceramic cad cam blocks
Trial: NCT00066443
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
Trial: NCT00066443
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
Trial: NCT00377468
Drug: Delta9-Tetrahydrocannabinol
RxNorm normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03140033
Drug: Misoprostol Oral Tablet
RxNorm normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
Trial: NCT03140033
Drug: Ranitidine Oral Tablet
RxNorm normalized name: ranitidine Oral Tablet
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at cord clamping the patient will recieve ranitidine sublingually
Trial: NCT01247324
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01247324
Drug: Ocrelizumab-matching placebo
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01247324
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01247324
Drug: Interferon beta-1a-matching placebo
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00648973
Drug: Diphenhydramine 50 mg
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet
Trial: NCT00648973
Drug: Diphenhydramine 25 mg
RxNorm normalized name: diphenhydrAMINE 25 mg oral tablet
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet
Trial: NCT00648973
Drug: Pseudoephedrine 120 mg
RxNorm normalized name: pseudoephedrine 120 mg oral tablet, extended release
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet
Trial: NCT00585052
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
Trial: NCT00532142
Drug: Intravitreal Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02106845
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
Trial: NCT01522794
Drug: NOX-H94
RxNorm normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single i.v. infusion
Trial: NCT03002428
Drug: Teriparatide (PF708)
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection
Trial: NCT03002428
Drug: Teriparatide (Forteo)
RxNorm normalized name: TERIPARATIDE (FORTEO) 250MCG/ML (600MCG) INJ,PEN,2.4ML
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection
Trial: NCT02015520
Drug: Clazakizumab
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00933712
Drug: LACTIC ACID(ND)
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
Trial: NCT02813369
Drug: naloxegol
RxNorm normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: non-interventional study where patients are exposed to naloxegol during normal clinical practice
Trial: NCT03112135
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
Trial: NCT03112135
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical TXA 1 gm diluted in 200 ml saline
Trial: NCT03112135
Drug: Adrenalin
RxNorm normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical adrenaline 1 mg diluted on 200 ml saline
Trial: NCT04400136
Drug: Lansoprazole oral tablets 30 mg
RxNorm normalized name: lansoprazole Disintegrating Oral Tablet
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post operative prescription
Trial: NCT02106845
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once daily orally 160 mg (4 tablets 40 mg)
Trial: NCT02098915
Drug: intravenous metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
Trial: NCT00003316
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00301808
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
Trial: NCT00301808
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 on day 1 of each cycle
Trial: NCT00301808
Drug: Pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
Trial: NCT02955056
Drug: Forsteo
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 micrograms/80 microlitres solution for injection in pre-filled pen
Trial: NCT01636687
Drug: Secukinumab 150mg
RxNorm normalized name: SECUKINUMAB 150MG/ML INJ,SYR,1ML
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
Trial: NCT01636687
Drug: Secukinumab 300mg
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
Trial: NCT00129376
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00367627
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02949583
Drug: chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
Trial: NCT01895023
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
Trial: NCT01895023
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
Trial: NCT01895023
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
Trial: NCT04004819
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A lower dosage of rituximab for HTLV-1-associated myelopathy
Trial: NCT01032798
Drug: mepivacaine
RxNorm normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
Trial: NCT02999022
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
Trial: NCT00453895
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg Sunitinib
Trial: NCT04034771
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol amp
Trial: NCT00906529
Drug: Levemir (Detemir) and Novolog (Aspart) Insulin
RxNorm normalized name: insulin detemir Injectable Solution [Levemir]
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
Trial: NCT00547469
Drug: DDP733
RxNorm normalized name: DDP733
DrugBank: DDP733 (DB05049)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01084031
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous propofol with sevoflurane inhalation induction
Trial: NCT01869946
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00362141
Drug: levetiracetam (add-on)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00034697
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00857116
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
Trial: NCT05346380
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
Trial: NCT00253110
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00253110
Drug: haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01691794
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01691794
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01606072
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 patients in 5 groups 4 each, advancing progressively to each dose level.
Trial: NCT00479635
Drug: TPI 287
RxNorm normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/m2 every three weeks for six cycles
Trial: NCT00479635
Drug: TPI 287
RxNorm normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
Trial: NCT02559102
Drug: Dexmedetomidine sedation
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive dexmedetomidine sedation
Trial: NCT01836133
Drug: Erlotinib 150 mg
RxNorm normalized name: erlotinib 150 MG
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00975715
Drug: Benzodiazepines
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines could be used as needed as rescue medication during the duration of the study.
Trial: NCT02344641
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01116596
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
Trial: NCT01814449
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
Trial: NCT00003465
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02520102
Drug: sargramostim GZ402664
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous
Trial: NCT00886314
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
Trial: NCT02559102
Drug: General sevoflurane anaesthesia
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive general sevoflurane anaesthesia with endotracheal intubation
Trial: NCT00532662
Drug: S(+)-ketamine
RxNorm normalized name: (S)-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
Trial: NCT01062087
Drug: Bupivacaine, Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
Trial: NCT03817476
Drug: BI 425809 (Treatment T1)
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intended commercial formulation tablet from batch 1 (iCF1)
Trial: NCT03817476
Drug: BI 425809 (Treatment T2)
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intended commercial formulation tablet from batch 2 (iCF2)
Trial: NCT01404598
Drug: naproxcinod 750 bid
DrugBank: Naproxcinod (DB06682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 750 bid
Trial: NCT03241017
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immunotherapy with Durvalumab after ASCT
Trial: NCT02607865
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration once-daily
Trial: NCT00670215
Drug: Ciprofloxacin single dose
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
Trial: NCT00670215
Drug: Ciprofloxacin triple dose
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
Trial: NCT02607865
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration once-daily
Trial: NCT00052364
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00377182
Drug: Copegus
RxNorm normalized name: Copegus
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000/1200mg po daily for 4 weeks
Trial: NCT00377182
Drug: PEGASYS
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms sc weekly for 4 weeks
Trial: NCT02092116
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Latency reversing agent